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1. Introduction
Dysphagia relates to swallowing problems due to physiological changes in aging people or
such factors as diseases and medications [1]. Previous studies stated that world prevalence of
dysphagia ranged between 16% and 22% [2]. Dysphagia can be classified into two types:
oropharyngeal and esophageal. Oropharyngeal dysphagia includes cerebrovascular disorders
(like stroke), central nervous system disorders (like Parkinson’s disease), and others (like
thyroid disorders). Esophageal dysphagia includes aging, alcoholism, diabetes mellitus (DM),
cancers, and medications [3]. Several symptoms detected to determine the type of dysphagia
(i.e. swallowing problems) included gastrointestinal symptoms (such as heartburn, indiges‐
tion, and gastro-esophageal reflux disease), respiratory symptoms (like cough), and muscu‐
loskeletal chest pain [4].
Many medications are known to induce dysphagia by affecting smooth and striated muscle
via increasing the sensitivity of mucosa resulting in swallowing difficulty. There are two
different ways in which this occurs. First, there is the normal adverse effect (or the indirect
effect) due to pharmacological action and complications such as dysphagia induced by
antibiotics as well as immunosuppressive and anti-cancer agents. Second, there is the direct
effect of medications irritating the mucosa, which is more observed in the elderly [5]. The aortic
arch is the area most susceptible to injuries induced by pills. Medications with a pH less than
3 (such as doxycycline and tetracycline) as well as certain slow-release anticholinergic dosage
medications were more caustic resulting in moderate and severe injuries [6]. The severity of
injuries depended on chronic irritation, high osmolarity, and the dissolution rate of dosage
forms [7]. Medications that are known to induce dysphagia can be categorized into four groups
[8]: (1) medications affecting smooth muscle such as theophylline and calcium channel
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blockers; (2) medications reducing esophageal sphincter pressure such as nitrates and atropine;
(3) medications inducing xerostomia such as antihypertensive agents and antiarrhythmics;
and (4) medications inducing esophageal injury such as aspirin and non-steroidal anti-
inflammatory medications.
Polypharmacy is  defined as  patient  use  of  five  or  more  medications  [9].  Polypharmacy
contributes  to  the  high  incidence  of  adverse  effects  as  a  consequence  of  possible  drug
interactions between medications [10, 11]. Although some studies state that polypharma‐
cy should be considered a significant predictor for dysphagia [2, 12], they have weakness‐
es in that they were either case reports or mainly dealt with specific dysphagia type. Thus,
the aims of the current study are, first, to describe the incidence, severity, and predictors
of dysphagia; second, to determine the relationship between polypharmacy and dyspha‐
gia;  and,  third,  to  describe  the  association  between  types  of  dysphagia  (depending  on
concurrent symptoms) and polypharmacy.
2. Methodology
2.1. Study design
The cross-sectional design based on patients self-reporting was used in the current study to
determine the incidence of dysphagia and its concurrent symptoms. The reason this study was
carried out at the Cardiac Clinic of Penang General Hospital was because polypharmacy is
more detectable in cardiac patients as a result of their treatment by chronic and multiple
therapies. There were 576 cardiac outpatients involved in the current study. Approval for this
study was granted by the Ministry of Health of Malaysia and consent forms were collected
from patients. All patients involved in the current study were aged 18 years or above, used
medications dispensed from the pharmacy of the hospital, and were able to understand and
fill in the questionnaire form in Standard Malay (Bahasa Malaysia) or English.
2.2. Self-reporting questionnaire and assessment of polypharmacy
The self-reporting questionnaire used in the current study had the purpose of counting the
incidence and severity of dysphagia and its symptoms. The validity of the questionnaire was
established after conducting language, panel, and statistical validity, after conducting a pilot
study, and after settling on an appropriate coefficient of reliability (Cronbach's α = 0.92).
Statistical advanced logistic regression was used to measure the specificity and sensitivity of
dysphagia and its symptoms, which had fixed in the questionnaire form. Patients were asked
to answer “yes” or “no” to questions about the existence of dysphagia and its symptoms.
Patients were also asked to report the severity of the symptoms as “mild”, “moderate”, or
“severe”. Mild referred to symptoms that did not bother the patient who had no need for
assistance. Moderate referred to patients who were bothered by symptoms but had no need
for assistance. Severe referred to patients who were seriously bothered by these symptoms
and had urgent need for assistance. Other information such as demographic data, medical
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history, and concurrent medications and diseases were taken from the progress files of
patients.
The patients included in this study were classified into three groups: (1) patients taking no
medications who were referred from other clinics for a follow-up; (2) patients already known
to the department taking fewer than 5 medications and (3) patients known to the department
taking 5 or more medications. All patients on medication had been in chronic therapy for at
least one year.
2.3. Statistical analysis
The Statistical Package for the Social Sciences (SPSS) software program was used to analyze
the results of the current study. The incidence and severity of dysphagia and its symptoms
were measured descriptively. The correlation between dysphagia and its symptoms was tested
using Spearman’s rank correlation. Multiple logistic regression was used, first, to find out the
effect of predictors’ interaction on the incidence of dysphagia; second, to discover how
polypharmacy impacted dysphagia; and, third, to determine the association between poly‐
pharmacy and type of dysphagia (oropharyngeal and esophageal). All the results of this study
were considered significant if their p values were less than 0.05.
3. Results
3.1. Demographic characteristics and medical information
The highest incidence of disease was found in males with a mean age of 59.11±10.14 years. The
most common diseases found in the current study were hypertension, DM, and ischemic heart
disease (IHD). The medications used the most were statins, aspirin, beta-blockers, and
angiotensin-converting enzyme inhibitors (ACE-Is). Other demographic characteristics and
medical information are illustrated in Table 1.
3.2. Severity of dysphagia types and its symptoms
The incidence (and percentage) of current patients complaining of dysphagia and its symp‐
toms during therapy were 122 (21.2%), 177 (30.7%), 265 (46%), and 286 (49.7%) for dysphagia,
indigestion, cough, and chest pain, respectively. Mild symptoms were the highest incidences
followed by moderate and severe (as shown in Figure 1).
Spearman’s rank correlation showed a positive significant (2-tailed, p< 0.001) relationship
between dysphagia and its symptoms. The correlation coefficient between dysphagia and its
symptoms was 0.322, 0.146, and 0.126 for indigestion, cough, and chest pain, respectively. This
result showed that the incidence of esophageal dysphagia was more frequent than that of
oropharyngeal dysphagia.
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3.3. Predictors of dysphagia
Gender,  IHD, and statins were the most significant factors that must be involved in the
regression model to insure the predictors of dysphagia could be determined (as shown in
Table 2).
Categorical variables χ2 df p
Gender 6.181 1 0.013
IHD 7.909 1 0.005
Statins 4.539 1 0.033
χ2 = chi-square test; df = degrees of freedom; p = calculated probability
Table 2. Categorical variables included in the regression model
Demographic data and diseases % (No.) Medications % (No.)
Gender (male) 74.3 (428) Statins 87.8 (506)
Age (≤65) 68.9 (397) Aspirin 67.4 (388)
Race Malay 39.6 (228) Beta-blockers 70.8 (408)
Chinese 28.5 (164) Calcium channel blockers 24.5 (141)
Indian 29.7 (171) ACE-Is 54 (311)
Other 2.3 (13) Angiotensin receptor blockers (ARBs) 10.6 (61)
Smoking 14.8 (85) Trimetazidine 29.2 (168)
Alcohol consumption 9.4 (54) Isosorbide dinitrate 23.1 (133)
Hypertension 65.8 (379) Thiazides 6.8 (39)
DM 39.9 (230) Furosemide 18.9 (109)
IHD 39.8 (229) Spironolactone 6.3 (36)
Arrhythmia 3.3 (19) Gliclazide 22.2 (128)
Renal disease 2.4 (14) Metformin 25 (144)
Thyroid diseases 2.3 (13) Digoxin 4.3 (25)




Table 1. Demographic characteristics and medical information of patients
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As a result  of  logistic  regression,  gender and IHD were found to be the significant risk
factors involved in the high incidence of dysphagia. Female cardiac patients had inciden‐
ces of dysphagia that were approximately 1.8 times higher than those of males. Patients
with IHD had incidences of dysphagia that were 1.8 times higher than those without (as
shown in Table 3).
Variable β SE OR 95% CI p
Gender Female 0.575 0.233 1.777 (1.148, 2.750) 0.010
Male (ref.)
IHD Yes 0.599 0.207 1.820 (1.212, 2.731) 0.004
No (ref.)
The reference category for the model is no dysphagia. The backward stepwise logistic regression test was used. The
Hosmer and Lemeshow goodness-of-fit test with χ2 (N = 576) = 3.365 and p =0.186
Table 3. Predictors of dysphagia in cardiac outpatients
3.4. Polypharmacy and its impact on dysphagia
Patients with polypharmacy (i.e. those using 5 or more medications) have a higher incidence
(45.84%) of dysphagia than other patients (as shown in Figure 2).
Binary logistic regression showed that medication use was a risk factor in the incidence of
dysphagia in cardiac outpatients. The incidence of dysphagia was about 2.8 and 3.2 times
higher for patients taking 1–4 drugs and those taking ≥ 5 drugs (polypharmacy), respectively,
than those taking no medications. However, the incidence of dysphagia in patients with





































Dysphagia and its symptoms
Mild Moderate Severe 
Figure 1. Incidence and severity of dysphagia and its symptoms
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Category β SE OR 95% CI p
1–4 drugs 1.144 0.491 2.842 (1.200, 8.223) 0.020
≥ 5 drugs 1.156 0.490 3.176 (1.216, 8.299) 0.018
No medications (ref.)
The reference category for the model is no dysphagia.
Table 4. The association between polypharmacy and dysphagia
3.5. Predictor interaction and impact on dysphagia
The impact of predictor interaction on the incidence of dysphagia according to binary logistic
regression showed gender and IHD to be two significant predictors. Patients taking 5 medi‐
cations or more (i.e. polypharmacy) were more susceptible to the incidence of dysphagia,
especially female patients and those with IHD.
Female cardiac patients taking 5 or more medications were about 2.2 times more prone to a
high incidence of dysphagia than males taking no medications, while there was no significant
impact on females taking fewer than 5 medications. This proved the impact polypharmacy has
on females complaining of dysphagia (as shown in Table 5).
IHD patients taking 5 medications or more had a significantly higher (about 1.9 times)
incidence of dysphagia than those free of IHD and taking no medications. However, no impact
was found for IHD patients taking less than 5 medications (as shown in Table 6).
These tables show the impact of polypharmacy is going to increase the incidence of dysphagia
when the interactions between predictors are taken into consideration. However, gender



























Figure 2. Percentage of medications used
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Category β SE OR 95% CI p
No. of drugs (gender) 0.012
1–4 drugs (female) 0.555 0.280 1.741 (1.006-3.015) 0.050
≥ 5 drugs (female) 0.770 0.306 2.159 (1.186-3.930) 0.012
The reference category is males taking no medications
The reference category for the model is no dysphagia
Table 5. Impact of polypharmacy and gender on dysphagia
Category β SE OR 95% CI p
No. of drugs (IHD) 0.022
1–4 drugs (IHD) 0.484 0.271 1.623 (0.954, 2.761) 0.074
≥ 5 drugs (IHD) 0.617 0.242 1.854 (1.154, 2.978) 0.011
The reference category is no medications and no IHD
The reference category for the model is no dysphagia
Table 6. Impact of polypharmacy and IHD on dysphagia
3.6. Polypharmacy and type of dysphagia
Dysphagia was classified according to symptoms of cardiac patients taking part in the study.
Chest pain is the only symptom that showed a significant association with polypharmacy.
Patients taking 5 or more medications had a significantly higher incidence of chest pain (about
2.1 times) than those without medications. Moreover, no significant effect was found for chest
pain in patients taking fewer than 5 medications. Thus, polypharmacy has a greater effect on
esophageal dysphagia than oropharyngeal dysphagia (as shown in Table 7).
4. Discussion
Many different results have been reported on the incidence of dysphagia in different areas of
the world as a consequence of the number of diseases and medications that bring it about.
Moreover, some studies have restricted themselves to different age groups; for example, some
relate to childhood dysphagia while others relate to geriatrics [13]. Many physicians fail to take
these symptoms into account either because they do not take dysphagia seriously or are
unfamiliar with the factors that bring it about [14]. Siebens et al [15] and Croghan et al [16]
found that morbidity and mortality were significantly higher in those with dysphagia than
those without because of malnutrition and/or low quality of life [17]. Speyer et al [18] and
Wallace et al [19] found that patients’ self-reporting was the most effective tool for identifying
dysphagia symptoms. This led to many studies being conducted on patients self-reporting
with the aim of determining the incidence of dysphagia [20–22]. This was because patients
were considered the main source of information to get at the data needed to conduct clinical
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studies. Unfortunately, very few studies have reported on the risk factors relating to dyspha‐
gia.
There are a number of benefits stemming from the current study: first, establishing a new
method to count the incidence of dysphagia by getting cardiac outpatients to fill in a validated,
acceptable, and feasible questionnaire, especially because until now there has been no standard
validated tool to report dysphagia and its symptoms capable of meeting clinical requirements
[23]. Second, this study can be used to determine the type of dysphagia based on the types of
symptoms by statistically correlating them into oropharyngeal and esophageal types; up until
now all previous studies either depended on one type or using scales for the classification.
Moreover, no study has ever been assigned to a specific clinical case such as the one here for
cardiovascular diseases or investigated the interactions of dysphagia predictors.
The survey carried out by Barczi et al [24] stated the incidence of adult patients complaining
of dysphagia ranged from 10 to 30%. The dysphagia incidence (21.2%) of the present study
was in the normal range, which was considered to be a good level of incidence when other
risks were taken into consideration; for example, the subjects involved in the current study
were elderly cardiac patients complaining of serious diseases and using chronic multiple
therapies. There is variance in the incidence of dysphagia symptoms such as cough, chest pain,
and indigestion. Such differences have also been reported in previous studies [25, 26]. The
reason for such differences is because the diseases affecting patients and the medications they
take differ from one patient to another. Compared with other studies, cough had a higher
incidence of dysphagia in the current study (46.7%), which was higher than incidence of
dysphagia, and this case was similar to the compared results of Eslick et al [27] who reported
dysphagia (16%), cough (27%) and chest pain (23%). Their study was based on different
explanations of different mechanisms of dysphagia [28, 29]. The incidence of mild, moderate,
and severe dysphagia in the present study was 71.31, 20.49, and 8.20%, respectively, which
was similar to the results of Eslick et al who reported 65, 30, and 5% for mild, moderate, and
severe, respectively [27].
Indigestion β SE OR 95% CI p
1–4 drugs -0.099 0.315 0.906 (0.488, 1.681) 0.754
≥ 5 drugs 0.130 0.311 1.139 (0.619, 2,079) 0.676
No medications (ref.)
Cough
1–4 drugs 0.040 0.291 1.041 (0.588, 1.842) 0.890
≥ 5 drugs 0.132 0.290 1.141 (0.647, 2.014) 0.648
No medications (ref.)
Chest pain
1–4 drugs 0.369 0.297 1.447 (0.808, 2.591) 0.214
≥ 5 drugs 0.748 0.296 2.113 (1.182, 3.777) 0.012
No medications (ref.)
The reference category is no dysphagia.
Table 7. Association between polypharmacy and type of dysphagia
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Dobrzycki et al found a significant association between IHDs and dysphagia, because the
shifting of parasympathetic levels increases the incidence of gastric reflex and induces cardiac
problems [30]. Similarly, cardiac patients in the current study considered IHDs to be the main
risk factors of dysphagia, where the incidence of dysphagia increased approximately 1.8 times
in patients complaining of IHDs. Alves et al found gender had a significant impact on the
incidence of dysphagia by measuring swallowing parameters such as velocity, intervals,
number, and volume capacity. The velocity at which females swallow was found to be slower
than for males, the volume capacity of females was found to be less than males, and females
were found to need more time to swallow [31]. There are two reasons for this. First, males have
larger oral and pharyngeal cavities than females; hence, they find it easier to swallow. Second,
some studies have reported that it takes longer for the esophageal sphincter to open in females
than in males [32, 33]. However, the results of the current study are in agreement with previous
studies regarding the relationship between gender and dysphagia; for example, there is a
higher incidence (approximately 1.8 times) of dysphagia in females than in males.
The reason polypharmacy can be considered a significant risk factor to the high incidence of
mortalities, morbidities, and serious adverse reactions, is because drug interactions increase
the potential toxicity of medications, especially in elderly patients [34]. The incidence of
polypharmacy detected varies widely between studies (22–82%) [35–39] as a result not only of
the way in which medications are prescribed in different countries but also awareness about
the risks of medications. The incidence of polypharmacy reported in the present study was
considered good (45.84%) when compared with other studies. Moreover, none of these studies
compared the incidence of dysphagia in healthy individuals and ill patients. Some patients in
the current study were not taking any medications because they had came from other clinics
for checking purposes only, making them a good standard group for comparison with those
with polypharmacy and those without polypharmacy.
Previous studies have found that polypharmacy has an effect on the incidence of dysphagia
and swallowing problems. However, these studies either were reports focused on types of
dosage forms, or conducted at community pharmacies for primary care patients [4, 40, 41]. The
present study has demonstrated significant clinical outcomes for the relationship between
polypharmacy and dysphagia, and provided evidence to show that number of medications
elevates the incidence of dysphagia in cardiac outpatients. In addition to these results, the
interactions of predictors were also investigated with significant positive outcomes. Females
with polypharmacy had a higher incidence of dysphagia than females without polypharmacy,
due to females with polypharmacy being more susceptible to adverse reactions of medications
[42]. Patients complaining of IHDs had a high incidence of polypharmacy, which elevates the
incidence of adverse drug reactions including dysphagia [43]. Thus, the present study has
shown that the incidence of patients with polypharmacy complaining of IHDs and reporting
dysphagia is high. The present study has satisfied theories about the interactions between
predictors and their impact on the incidence of adverse reactions. Few studies have investi‐
gated the synergistic effect of predictors on the incidence of dysphagia, which gives the current
study importance in providing a new clinical viewpoint.
Impact of Polypharmacy on Deglutition in Patients with Coronary and Cardiac Diseases
http://dx.doi.org/10.5772/61085
49
A final novel result concerns the classification of dysphagia induced by polypharmacy in
cardiac outpatients. There has yet to be a study determining the effects of polypharmacy on
the incidence of dysphagia, let alone the type of dysphagia. The present study found that chest
pain had a greater association with polypharmacy than other symptoms. By correlating the
symptoms of dysphagia, the study found that polypharmacy is likely to induce a higher
incidence of esophageal dysphagia due to the significant irritation (e.g. of the mucosa) of
medications and physiological changes with aging. Despite being unable to pinpoint a specific
medication as the main causative agent for inducing a high incidence of dysphagia, the
cumulative impact of polypharmacy was a prime candidate. Therefore, the current study
suggests that the effect of total number of medications (polypharmacy) is greater than the effect
of the medication itself, possibly due to the interactions and adverse reactions of medications.
5. Conclusion
Patients’ self-reporting was considered the optimal method to gather information on adverse
symptomatic effects like dysphagia. Polypharmacy, female patients, and IHDs are the main
predictors for dysphagia. Despite these predictors being non-preventable, polypharmacy
control can minimize the incidence and severity of dysphagia induced by medications. The
authors of the present study recommend healthcare professionals (especially pharmacists) to
do their utmost to reduce the number of prescribed medications (according to the guidelines
of polypharmacy), because they are more aware than most of adverse drug reactions and drug
interactions.
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